Skip to main content

Table 3 Proportion of participants with a dose shift ≥1 doubling concentration post-treatment

From: The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study

Time Post-Dose LAMA, n = 15 uLABA, n = 16 Combo, n = 14
1 h 100% (15/15) 62.5% (10/16) 100% (14/14)
24 h 73.3% (11/15) 37.5% (6/16) 64.3% (9/14)
48 h 80% (12/15) 18.8% (3/16) 64.3% (9/14)
  1. LAMA, long-acting muscarinic antagonist; uLABA, ultra-long acting β2 agonist; Combo, combination therapy